| Randle T. Middleton Md, P.c | |
|
2089 Cecil Ashburn Dr Se Suite 101 Huntsville AL 35802-2567 | |
| (256) 882-7351 | |
| (256) 489-2322 |
| Full Name | Randle T. Middleton Md, P.c |
|---|---|
| Speciality | Family Medicine |
| Location | 2089 Cecil Ashburn Dr Se, Huntsville, Alabama |
| Authorized Official Name and Position | Randle Thomas Middlton (OWNER) |
| Authorized Official Contact | 2568827351 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Randle T. Middleton Md, P.c 2089 Cecil Ashburn Dr Se Suite 101 Huntsville AL 35802-2567 Ph: (256) 882-7351 | Randle T. Middleton Md, P.c 2089 Cecil Ashburn Dr Se Suite 101 Huntsville AL 35802-2567 Ph: (256) 882-7351 |
| NPI Number | 1033356373 |
|---|---|
| Provider Enumeration Date | 01/08/2009 |
| Last Update Date | 11/09/2012 |
| Medicare PECOS PAC ID | 8820151186 |
|---|---|
| Medicare Enrollment ID | O20090113000183 |
News Archive
In this "End the Neglect" blog post, Alanna Shaikh, a writer for U.N. Dispatch, follows up on her previous post in which she asserts that "there is a single approach that will help to fight both" non-communicable diseases (NCDs) and neglected tropical diseases (NTDs), writing that in order to tackle both types of diseases "we can improve governance and we can strengthen health systems."
IntegriChain, Inc., a leading provider of informatics and data enrichment services to the pharmaceutical industry was identified by Inc. 500 as #391 on the list of fastest growing private companies in America. Despite the general economic slowdown, IntegriChain's innovative approach to leveraging their customers' existing information assets has led to a three year growth rate of over 750%.
Scientists at the Salk Institute and Beth Israel Deaconess Medical Center in Boston have discovered a new class of molecules—produced in human and mouse fat—that protects against diabetes.
Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand.
The Chicago Biomedical Consortium is announcing a $3 million Infrastructure Initiative to promote investment in high-impact, next-generation scientific equipment at its member universities. The Initiative aims to make modern and powerful tools available to the CBC research community at a time when federal grants for scientific infrastructure are scarce.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033356373 | NPI | - | NPPES |
| 000038324 | Other | AL | MEDICARE PROVIDER NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 18862 (Alabama) | Primary |
| Provider Name | Randle T Middleton |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801845920 PECOS PAC ID: 0648280669 Enrollment ID: I20090113000170 |
News Archive
In this "End the Neglect" blog post, Alanna Shaikh, a writer for U.N. Dispatch, follows up on her previous post in which she asserts that "there is a single approach that will help to fight both" non-communicable diseases (NCDs) and neglected tropical diseases (NTDs), writing that in order to tackle both types of diseases "we can improve governance and we can strengthen health systems."
IntegriChain, Inc., a leading provider of informatics and data enrichment services to the pharmaceutical industry was identified by Inc. 500 as #391 on the list of fastest growing private companies in America. Despite the general economic slowdown, IntegriChain's innovative approach to leveraging their customers' existing information assets has led to a three year growth rate of over 750%.
Scientists at the Salk Institute and Beth Israel Deaconess Medical Center in Boston have discovered a new class of molecules—produced in human and mouse fat—that protects against diabetes.
Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand.
The Chicago Biomedical Consortium is announcing a $3 million Infrastructure Initiative to promote investment in high-impact, next-generation scientific equipment at its member universities. The Initiative aims to make modern and powerful tools available to the CBC research community at a time when federal grants for scientific infrastructure are scarce.
› Verified 2 days ago
News Archive
In this "End the Neglect" blog post, Alanna Shaikh, a writer for U.N. Dispatch, follows up on her previous post in which she asserts that "there is a single approach that will help to fight both" non-communicable diseases (NCDs) and neglected tropical diseases (NTDs), writing that in order to tackle both types of diseases "we can improve governance and we can strengthen health systems."
IntegriChain, Inc., a leading provider of informatics and data enrichment services to the pharmaceutical industry was identified by Inc. 500 as #391 on the list of fastest growing private companies in America. Despite the general economic slowdown, IntegriChain's innovative approach to leveraging their customers' existing information assets has led to a three year growth rate of over 750%.
Scientists at the Salk Institute and Beth Israel Deaconess Medical Center in Boston have discovered a new class of molecules—produced in human and mouse fat—that protects against diabetes.
Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand.
The Chicago Biomedical Consortium is announcing a $3 million Infrastructure Initiative to promote investment in high-impact, next-generation scientific equipment at its member universities. The Initiative aims to make modern and powerful tools available to the CBC research community at a time when federal grants for scientific infrastructure are scarce.
› Verified 2 days ago
Bptcare Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 311 Longwood Dr, Sw, Huntsville, AL 35801 Phone: 256-534-5946 Fax: 256-534-3041 | |
Inspirational Counseling Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4100 Market St Ste 100, Huntsville, AL 35808 Phone: 256-210-4925 | |
Gleneagles Family Medicine Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1102 Gleneagles Dr Sw, Huntsville, AL 35801 Phone: 256-881-5880 Fax: 256-883-3280 | |
Magnolia Primary Care Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4245 Balmoral Dr Sw Ste 102, Huntsville, AL 35801 Phone: 256-203-6676 Fax: 833-979-0980 | |
Five Points Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 502 Pratt Ave Ne, Huntsville, AL 35801 Phone: 256-714-3363 | |
Davis Medical Group, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7850 Memorial Pkwy Sw, Huntsville, AL 35802 Phone: 256-882-0132 Fax: 256-882-1461 | |
Crestani Family Medicine, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2745 Bob Wallace Ave Sw, Suite D, Huntsville, AL 35805 Phone: 256-534-1323 Fax: 256-534-1780 |